Lymphoma, Malignant Clinical Trial
Official title:
An Open-Label, Phase 1, Two-Way, Crossover Study of the Effect of Food on the Pharmacokinetics of TAK-659 in Patients With Advanced Solid Tumor and/or Lymphoma Malignancies
The purpose of this study is to characterize the effect of food on the single-dose PK of TAK-659 in participants with advanced solid tumors and/or lymphomas.
The drug being tested in this study is called TAK-659. TAK-659 is being tested in participants with advanced solid tumors and/or lymphomas in order to determine the effect of food on the PK of single oral dose of TAK-659 tablet formulation. The study will enroll approximately 20 participants. Participants will be randomly and equally assigned (by chance, like flipping a coin) to 1 of the 2 treatment sequences following as: - TAK-659 100 mg Fasted + TAK-659 100 mg Fed - TAK-659 100 mg Fed + TAK-659 100 mg Fasted All participants will be asked to take single oral dose of TAK-659 tablet on Day 1 and Day 8 of a 15-day food effect treatment period. Upon completion of the food effect treatment period, participants can continue in the optional post food effect treatment period to receive TAK-659 100 mg, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicity, or the start of another anticancer therapy upon request by the investigator and agreement by the project clinician. This single or multi-center trial will be conducted in the United States. The overall time to participate in this study is up to 58 weeks. Participants will visit the clinic on Day -1 and remain confined until Day 15 of food effect treatment period. Participants will make a visit to the clinic after 28 days after last dose of study drug for a follow-up assessment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
| Completed |
NCT00600353 -
Multi-day Doses in Prevention of Nausea and Emesis
|
Phase 2 | |
| Completed |
NCT01432951 -
A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
|
Phase 1 | |
| Completed |
NCT02249429 -
Open-Label, Non Randomized Phase 2 Study With Safety Run-In
|
Phase 2 | |
| Terminated |
NCT02440685 -
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02732275 -
DS-3201b in Participants With Lymphomas
|
Phase 1 | |
| Completed |
NCT00509184 -
Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma
|
Phase 2 | |
| Recruiting |
NCT00619879 -
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
|
Phase 3 | |
| Completed |
NCT00146055 -
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood
|
Phase 2 | |
| Completed |
NCT00741871 -
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
|
Phase 1 | |
| Recruiting |
NCT04947618 -
Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim
|
||
| Recruiting |
NCT02441972 -
Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
|
Phase 1 | |
| Completed |
NCT00078637 -
Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma
|
Phase 1 | |
| Completed |
NCT00037791 -
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
|
Phase 3 | |
| Completed |
NCT01388335 -
A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin
|
Phase 1 |